News

ASH 2025: ‘Ready-made’ T-cell gene therapy tackles ‘incurable’ T-cell leukaemia

ASH 2025: Continuous and fixed-duration treatments result in similar outcomes for CLL

Study finds most people trust doctors more than AI but see its potential for cancer diagnosis

ASH 2025: Measurable residual disease shows strong potential as an early indicator of survival in acute myeloid leukaemia

Key protein helps breast cancer cells survive in hostile conditions

ASH 2025: Milder chemo works for rare, aggressive lymphoma

A routine blood test could help predict who benefits most from CAR T-cell therapy

Novel AI technique able to distinguish between progressive brain tumours and radiation necrosis

Study finds childhood leukaemia aggressiveness depends on timing of genetic mutation

ASH 2025: Delayed toxicities after CAR T cell therapy for multiple myeloma are connected and potentially preventable

ASH 2025: Researchers identify CD40 as potential biomarker for a type of nodal T cell lymphoma

ASH 2025: Results show long-lasting benefits of CAR T cell therapy for hard-to-treat lymphoma